Arzoxifene: the evidence for its development in the management of breast cancer by Jackson, Lee R. et al.
Proof of concept review
Arzoxifene: the evidence for its development in the
management of breast cancer
Lee R. Jackson1, Kwok L. Cheung1, Aman U. Buzdar2, John F. R. Robertson1
1Professorial Unit of Surgery, Nottingham City Hospital, Nottingham, UK; 2The University of Texas, M.D.
Anderson Cancer Center, Houston, Texas, USA
Abstract
Introduction: Endocrine therapy is an important and integral part of breast cancer management. Selective estrogen receptor modulators
(SERMs), such as tamoxifen, remain a vital component in the endocrine therapy armamentarium. However the “ideal SERM”, which has
antagonist effects on the breast and endometrium but beneficial agonistic effects on bone and lipid profile, remains to be found.
Aim: The aim of this review is to examine the evidence for arzoxifene as the “ideal SERM.”
Evidence review: Arzoxifene showed initial promise as the “ideal SERM” in preclinical, phase I, and phase II clinical studies. It appeared
to have powerful antiestrogenic effects on breast cancer and endometrium, with equally strong favorable estrogenic effects on bone and
lipid profile, minimal side effects, and good oral bioavailability.
However, phase III trial data found it to be inferior to tamoxifen, bringing an apparent end to its investigation as a breast cancer treatment.
Clinical potential: Despite early promise as the “ideal SERM”, results from a phase III trial have relegated arzoxifene to research in breast
cancer prevention and osteoporosis treatment.
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Core evidence proof of concept summary for arzoxifene in breast cancer
Outcome measure Emerging evidence
Breast cancer cell growth Estrogen-stimulated MCF-7 breast cancer cell line proliferation was inhibited by arzoxifene to a degree superior to
that with tamoxifen and equivalent to raloxifene
N-nitrosomethylurea-induced mammary cancer growth in rats inhibited with an ability superior to raloxifene but
similar to tamoxifen
Effects on the endometrium Arzoxifene has no significant estrogenic effect on endometrium
Maintenance of bone density and strength At least as effective as raloxifene in vivo. Evidence of an antiresorptive effect on bone in postmenopausal women
Effects on cholesterol and body weight Arzoxifene prevents increase in cholesterol to at least same degree as raloxifene; also prevents body weight
increase in vivo
Endocrine effects Arzoxifene decreases follicle-stimulating hormone and luteinizing hormone levels with increasing sex hormone-
binding globulin levels to similar extent as tamoxifen
Serum and urine osteocalcin levels decreased in vivo
Response rates Objective response rate (ORR) (defined as CR + PR) achieved in 19.2–40.5% patients with arzoxifene 20 mg/day,
and in 7.4–36.4% with 50 mg/day
Clinical benefit rate (CBR) (defined as CR + PR + stable disease ≥6 months) achieved in 28.8–64.3% for arzoxifene
20 mg/day, and in 20.4–61.4% with 50 mg/day
ORR rate and CBR rates lower than with tamoxifen 20 mg/day
Time to disease progression Progression-free survival 4 months with arzoxifene 20 mg/day compared with 7.5 months with tamoxifen 20 mg/day
Arzoxifene less effective than tamoxifen
Tolerability Acceptable tolerability profile
CR, complete response; PR, partial response.Scope, aims, and objectives
Breast cancer remains the most common cancer in women in the
Western world (Office for National Statistics 2007; Ries et al. 2007).
A significant number of breast cancers are related to exposure to
estrogens, either endogenous or exogenous, and more than 75%
of breast cancers are hormone receptor positive (Chlebowski et al.
2003; M￼nster et al. 2006). Hence, manipulation of circulating/local
estrogen/progesterone or suppression of the estrogen or
progesterone receptors remains an essential part of the treatment
and prevention of breast cancer (Early Breast Cancer Trialists’
Collaborative Group 1996, 1998, 2005).
A wide range of drugs has been developed since Beatson,
in 1896, first reported that breast cancer could be treated by
oophorectomy (Beatson 1896). These agents are collectively
known as endocrine therapies and can be divided into “ablative”
(where the aim is to remove the source of estrogen) and “additive”
(where the aim is to interfere with the effect of estrogen on the
hormonally dependent cancer cells) (Hayes & Robertson 2002).
While ablative therapies were initially delivered via surgical means
(e.g. oophorectomy, adrenalectomy, and hypophysectomy), this is
now possible through drug treatments such as luteinizing
hormone-releasing hormone (LHRH) agonists/antagonists (e.g.
goserelin) and the aromatase inhibitors (e.g. anastrazole,
letrozole, and exemestane). Additive agents range from
androgens (methyl testosterone), estrogenic compounds
(diethylstilbestrol, ethinylestradiol), progestins (megestrol acetate,
medroxyprogesterone acetate), antiprogestins (mifepristone,
onapristone), selective estrogen receptor modulators [(SERMS),
such as tamoxifen], and pure antiestrogens (such as fulvestrant).
The success of tamoxifen in the treatment (Early Breast Cancer
Trialists’ Collaborative Group 1996, 1998, 2005) and prevention
(Fisher et al. 1998; Cuzick et al. 2007; Powles et al. 2007) of breast
cancer, together with the difference in cost compared with the
new aromatase inhibitors, continue to make SERMS the most
widely used form of endocrine therapy worldwide. It is well
established that tamoxifen has both antagonistic and partial
agonistic properties depending on target tissues. Over the years
unwanted agonistic side effects of tamoxifen, such as uterine
cancer, have become recognized, such that attention has been
focused on developing new SERMs with different profiles.
The nonsteroidal SERMS can be categorized into
triphenylethylenes (e.g. tamoxifen, toremifene, droloxifene,
idoxifene, trichlorophenyethylene, and tribromophenylethylene)
and benzothiophenes (e.g. raloxifene and arzoxifene). These
modulators have variable estrogenic effects on target tissues
dependent upon selective gene coactivator or co-repressor
recruitment (Grese et al. 1997; Shang & Brown 2002; Cuzick et al.
2007). Hence, although tamoxifen is antiestrogenic to breast
tissue, it has proestrogenic (agonistic) effects on bone and
endometrium. While the occurrence of endometrial cancer is
clearly undesirable, the increased risk has been perceived as
small relative to the substantial benefits that tamoxifen has on
reducing breast cancer events (i.e. recurrence and mortality). The
aim of SERM development has been to find an “ideal” SERM
(M￼nster 2006), one that has antiestrogenic effects on breast and
endometrium, whilst having beneficial estrogenic effects on bone
and lipid profiles. In addition, it would be expected not to cause
hot flushes or thromboembolic events, nor to be associated with
long term exposure tumor dependence as seen with tamoxifen
(Gottardis & Jordan 1988; Osipo et al. 2005), which may explain
development of tumor resistance (Osborne & Fuqua 1994;
Johnston 1997).
Arzoxifene was designed in an attempt to deliver the ideal SERM.
The aim of this review is to evaluate the evidence for arzoxifene
as the ideal SERM in the management of breast cancer.
Methods
PubMed was searched using the keywords “arzoxifene”,
“arzoxifene AND breast cancer”, and “arzoxifene AND
endometrial cancer”. The initial search yielded 71 references;
adding the keywords “breast cancer” and “endometrial cancer”
resulted in 46 and 11 references, respectively, although none were
additional to the original 71. A further 33 additional references
were added from evidence acquired via the original PubMed
search (Table 1).
Arzoxifene development
When discussing the development of arzoxifene, it is important to
consider results obtained with other SERMs, notably raloxifene.
Benzothiophene SERMs began development in 1980 (Black &
Goode 1980), LY-156758 (raloxifene) being one of the first to
begin evaluation. It had been noted to have antiestrogenic effects
on breast cancer cell lines and endometrial cells, whilst having
proestrogenic effects on bone (Palkowitz et al. 1997). However, in
a phase II trial in patients with metastatic breast cancer, raloxifene
showed little or no therapeutic effect: there were no objective
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Category Number of records
Full papers Abstracts
Initial search 71 0
records excluded 57 0
records included 14 0
Additional studies identified 33 2
Level 1 clinical evidence (systemic
review, meta analysis)
19 1
Level 2 clinical evidence (RCT) 10
Level ≥3 clinical evidence 50
trials other than RCT case reports
Nonclinical trial evidence 22 1
Economic evidence 00
For definitions of levels of evidence, see Editorial Information on inside back cover or on
Core Evidence website (http://www.coremedicalpublishing.com).
RCT, randomized controlled trial.
Table 1 | Evidence base included in the review253
responses to raloxifene 200 mg daily in 14 patients who had
progressed on tamoxifen after initially responding to that agent
(Buzdar et al. 1988). Raloxifene, at this stage, was not developed
further for breast cancer treatment, with efforts being refocused
on its potential use in osteoporosis and breast cancer
prophylaxis. The Multiple Outcomes of Raloxifene Evaluation
(MORE) trial, in 7705 postmenopausal osteoporotic women
randomized to raloxifene or placebo, showed that raloxifene
significantly improved bone mineral density in the femoral neck
and spine, and significantly reduced the risk of a vertebral fracture
[relative risk reduction (RRR) 30–50%] (Ettinger et al. 1999). At
early analysis, raloxifene was also reported to be associated with
a significant 76% reduction in breast cancer incidence
(Cummings et al. 1999). This persisted in long term follow-up with
a significant 72% reduction in the incidence of breast cancer,
which comprised an 84% reduction in incidence of estrogen
receptor-positive breast cancers, with no effect on the incidence
of estrogen receptor-negative breast tumors (Cauley et al. 2001).
Although raloxifene significantly increased the risk of
thromboembolism [relative risk (RR), 3.1], it had no significant
effect on the incidence of endometrial cancer. In an extension of
the MORE study, women who had been on raloxifene for 4 years
were offered a further 4 years of treatment – the Continuing
Outcomes Relevant to Evista (CORE) study. This reported a 69%
reduction in breast cancer incidence due to raloxifene (Martino et
al. 2004). When the MORE and CORE trials were both considered
(i.e. analyzing all 8 years of raloxifene therapy) the overall
reduction in breast cancer incidence was 66%, with a 76%
reduction in estrogen receptor-positive breast cancer. The
increased thromboembolism risk persisted (RR=2.17).
The National Surgical Adjuvant Breast and Bowel Project (NSABP)
Study of Tamoxifen and Raloxifene (STAR) phase II trial arose out
of the findings of the MORE and CORE studies. STAR was a
large, prospective, double-blind, randomized trial in which
19 747 postmenopausal women with a greater than 1.66% 5-year
risk of developing breast cancer were randomized to either
tamoxifen 20 mg daily or raloxifene 60 mg daily. The NSABP
phase I study had already shown tamoxifen to significantly reduce
the risk of breast cancer in high risk women by 49% (Fisher et al.
1998). The phase II trial showed raloxifene was equally effective
as tamoxifen at preventing invasive breast cancer, which was the
primary endpoint of the trial (Vogel et al. 2006). Raloxifene, unlike
tamoxifen, did not appear to be effective at preventing in-situ
cancers (RR 1.4), although this difference was not statistically
significant. Other secondary endpoints showed that compared
with tamoxifen there were 38% fewer uterine cancers, 30% fewer
thromboembolic events, 21% fewer cataracts, and 18% fewer
cataract surgeries. Only the incidence of cataract was
significantly different between the two SERMs. Raloxifene did not
differ from tamoxifen in terms of the incidence of ischemic heart
events, strokes, or fractures. Quality of life was also statistically
similar for the two drugs (Land et al. 2006). Raloxifene was
associated with more musculoskeletal symptoms, dyspareunia,
and weight gain, but fewer gynecologic problems, vasomotor
symptoms, leg cramps, and bladder control problems (Land et al.
2006). Raloxifene had therefore shown its usefulness in
prevention of osteoporosis and vertebral fracture, and at breast
cancer prevention. However it had not demonstrated any efficacy
as a treatment for established breast cancer.
Arzoxifene was developed as the next generation SERM to
determine if the benzothiophenes could still have a role in breast
cancer treatment. It is a raloxifene analog with an oxygen
modification of raloxifene’s carbonyl site. This seemed to increase
the estrogen receptor binding affinity and antiestrogenic properties,
as well as improving oral bioavailability (Palkowitz et al. 1997; Suh et
al. 2001). Arzoxifene offered apparent potent antiestrogenic effects
on breast and endometrial cells, whilst having beneficial estrogenic
effects on bone and cholesterol metabolism (Palkowitz et al. 1997).
Arzoxifene is rapidly metabolized to desmethylated arzoxifene (LY-
335563). The metabolite is active with high estrogen receptor affinity
and ability to inhibit breast cancer (MCF-7) cell lines (Freddie et al.
2004). Indeed the metabolite seems to be a more potent inhibitor of
MCF-7 cells than both tamoxifen and arzoxifene itself (Freddie et al.
2004). Studies in rats and monkeys show variable extent of
metabolism between species (M￼nster 2006), with prolonged half-
lives for parent compound and metabolite in the latter. Fecal
elimination predominates, with minimal urinary excretion.
Preclinical studies
Arzoxifene has demonstrated an ability to inhibit breast cancer
cell growth in both in-vitro and in-vivo models. In vitro, the parent
compound and metabolite show strong inhibition of the estrogen
receptor-positive MCF-7 breast cancer cell line, including those
demonstrating tamoxifen resistance (Freddie et al. 2004).
Estrogen-stimulated MCF-7 breast cancer cell line proliferation
was inhibited by arzoxifene to a degree superior to that of
tamoxifen and equivalent to raloxifene (Suh et al. 2001).
Arzoxifene also displayed inhibition of basal proliferation of these
cell lines in the absence of estrogen, whereas tamoxifen
stimulated basal proliferation (Suh et al. 2001).
In-vivo arzoxifene inhibited MCF-7 breast cancer xenograft growth
in oophorectomized athymic mice (Detre et al. 2003), to a similar
degree as tamoxifen. In addition, it prevented mammary cancer
growth in rats induced by the carcinogen N-nitrosomethylurea,
with an ability superior to raloxifene but similar to tamoxifen (Suh
et al. 2001). Some evidence has been found of cross-resistance
with tamoxifen (Schafer et al. 2001), with ongoing tumor growth in
transplanted athymic mice in one tamoxifen stimulated tumor
model (MCF-7), but not in another (T47D).
In the uterus, arzoxifene inhibited the agonistic effect of estrogen
on endometrial cell growth (Palkowitz et al. 1997; Sato et al. 1998;
Suh et al. 2001), but also did not in itself stimulate uterine
hypertrophy or endometrial cell proliferation (Palkowitz et al.
1997; Sato et al. 1998; Suh et al. 2001; Ma et al. 2002). It has also
demonstrated an ability to inhibit a tamoxifen-na￯ve endometrial
cancer cell line, but has no effect on tamoxifen- or estrogen-
stimulated endometrial tumors (Dardes et al. 2001).
With regard to bone health, arzoxifene maintains bone mineral
density in oophorectomized rats, equal to that seen with estrogen
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strength and toughness were higher compared with that seen in
untreated oophorectomized rats (Ma et al. 2002).
Cholesterol levels were prevented from rising in oophorectomized
rats by as much as 59% with arzoxifene (Palkowitz et al. 1997; Sato
et al. 1998; Ma et al. 2002), which was an effect at least equivalent
to that with estrogen and raloxifene, although arzoxifene
demonstrated superior potency achieving the same cholesterol
reduction for half the dose of raloxifene (Sato et al. 1998).
Arzoxifene was also reported to prevent body weight increase in
oophorectomized rats (Sato et al. 1998; Ma et al. 2002), mainly
due to reduced gain of fat mass (Ma et al. 2002). Ovarian cysts
were induced by arzoxifene in some species (M￼nster 2006).
Arzoxifene reduced estrogen receptor expression in endometrial
cancer cell lines (ECC-1) (Dardes et al. 2001), an effect that was
not reproducible in breast cancer cell lines (MCF-7) (Detre et al.
2003). Finally, unlike tamoxifen, long-term exposure in athymic
mice did not produce any arzoxifene-stimulated transplantable
tumors (Schafer et al. 2001), representing a further apparent
advantage over tamoxifen.
These studies set the scene for arzoxifene as a potential
candidate for an ideal SERM: inhibition and prevention of breast
cancer at least as effective as tamoxifen, no stimulatory effects on
the endometrium, maintenance of bone density and strength at
least as effective as raloxifene, beneficial effects on cholesterol
and weight, and no long-term exposure effects.
Outcomes achieved in clinical development
Phase I trials
With at least raloxifene equivalence and suggestion of superiority
over tamoxifen, these promising preclinical data with arzoxifene
prompted a phase I trial in women with metastatic breast cancer
(M￼nster et al. 2001). Previous animal studies had shown
biological activity at a human equivalent dose of 10 mg/day;
furthermore a parallel study in healthy volunteers showed doses
of 25 mg/day and 100 mg/day had similar effects on fibrinogen,
biochemical bone markers, low density lipoprotein (LDL),
cholesterol, and gonadotrophin concentrations (M￼nster et al.
2001). Hence four dose regimens of 10 mg/day, 20 mg/day,
50 mg/day, and 100 mg/day were chosen for evaluation.
Thirty-two women, all with metastatic estrogen receptor- and/or
progesterone receptor-positive breast cancer, were selected: 9%
were premenopausal, 47% had liver metastases, median age was
56 years, and the patients had had a median of one prior
chemotherapy and two hormonal therapy regimens. All had
previously received tamoxifen.
There was a significant decrease in follicle-stimulating hormone
(FSH) and luteinizing hormone (LH) levels, along with an increase
in sex hormone-binding globulin (SHBG). Urine osteocalcin (a
marker of bone resorption) levels decreased, suggesting a bone
health benefit. There were no objective responses (complete,
partial, or minor), although 19% of patients had stable disease for
≥6 months [median 7.7 months (range 6–34)].
The plasma concentration of arzoxifene was linear with dose, and
there were no dose-limiting toxicities. Hot flushes were the most
common (56%) side effect, with no dose-dependent change in
frequency. Less frequent were rash (9%), vaginal bleeding (6%),
pruritis (6%), and constipation, headache, and stomatitis (3% each).
There was no effect on the endometrium based on transvaginal
ultrasound (TVU) on 15 patients after 12 weeks’ treatment, and no
ovarian cysts developed. There was one deep vein thrombosis and
one pulmonary embolus, although both occurred in patients with
other risk factors for thromboembolic events.
Overall, this trial demonstrated arzoxifene to be safe and well
tolerated, with a possible benefit in patients with heavily
pretreated metastatic breast cancer.
Further phase I trials (Fabian et al. 2004) evaluated arzoxifene in
the preoperative setting. Arzoxifene 10 mg/day, 20 mg/day, or
50 mg/day was used 2–6 weeks prior to surgical resection of an
invasive or in-situ breast cancer. Although interpretation was
limited by the small sample size, arzoxifene appeared to lower
proliferation markers including proliferating cell nuclear antigen
(PCNA), insulin-like growth factor (IGF)-1 and IGF-binding protein-
3 (IGFBP-3), decrease estrogen expression and LH levels, and
increase SHBG levels. These effects seemed most pronounced
with the 20 mg/day and 50 mg/day doses.
Phase II trials
Breast cancer
The phase I trials set the stage for phase II trials where arzoxifene
was compared at two doses (20 mg/day and 50 mg/day) in two
separate randomized, double-blind trials in women with
hormone-sensitive metastatic breast cancer (Baselga et al. 2003;
Buzdar et al. 2003). In the predominantly American trial (Buzdar et
al. 2003), 112 women with metastatic breast cancer were
recruited, with substratification into tamoxifen-sensitive (no prior
tamoxifen exposure or recurrence >12 months postadjuvant
tamoxifen completion) or tamoxifen-refractory (relapse or
progression whilst on tamoxifen) groups. Treatment continued
until disease progression, unacceptable toxicity, or informed
consent was withdrawn. Median or mean follow-up time was not
stated. In the predominantly European trial (Baselga et al. 2003),
92 women with locally advanced stage IIIB disease (35%) or
metastatic disease were recruited for 12 weeks’ treatment or until
disease progression. Although 9% had prior adjuvant tamoxifen
therapy, there was no subcategorization into tamoxifen sensitive
or refractory. Average follow-up time was 22 months.
In both trials the objective response rate [ORR; defined as
complete response (CR) + partial response (PR)] was numerically
higher for arzoxifene 20 mg/day versus 50 mg/day (Table 2); rates
were 40.5% versus 36.4% in the European trial (Baselga et al.
2003), and 19.2% versus 7.4% in the American trial (Buzdar et al.
2003). A similar trend was seen for clinical benefit rate
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(CBR; defined as CR + PR + stable disease ≥6 months) where the
figures were 64.3% for arzoxifene 20 mg/day versus 61.4% with
50 mg/day in the European trial, and 28.8% versus 20.4% in
the American trial. ORR and CBR were lower in tamoxifen-
refractory patients than in the tamoxifen-sensitive group
(Buzdar et al. 2003), with a similar trend of 20 mg performing
better than 50 mg (Table 3). In the tamoxifen-sensitive group, ORR
was 30.4% and 8.0% for arzoxifene 20 mg and 50 mg,
respectively, and CBR was 47.8% and 32.0%. The corresponding
rates in the tamoxifen-refractory group were 10.3% with
arzoxifene 20 mg/day versus 6.9% with 50 mg/day for ORR, and
13.8% versus 10.3%, respectively, for CBR (Buzdar et al. 2003).
Hence 20 mg/day arzoxifene had a numerical (although not
statistical) advantage in ORR and CBR over 50 mg/day, and was
more effective in tamoxifen-sensitive patients.
In terms of hormone and bone biomarkers, the European trial
showed a significant decrease in FSH and estradiol levels in
postmenopausal women, and a significant increase in SHBG levels
for both arzoxifene doses, with a significant decrease in LH levels
for the 50 mg/day dose only (Baselga et al. 2003), although there
was no significant difference between the two dosages. The
American trial did not show these changes overall, although when
analyzed according to menopausal status there was a decrease in
FSH and LH levels, and an increase in SHBG level in post-
menopausal women. There was a significant decrease in serum
osteocalcin levels in postmenopausal women with both arzoxifene
doses in the European trial and only with the 50 mg/day dose in the
American trial. In neither trial were there enough premenopausal
women to make reliable inferences on biomarker levels.
The top five clinical toxicities in the American trial were hot flushes
(46%), nausea (22%), cutaneous side effects (6%), neuromotor
toxicity (5%), and weight gain (5%). In the European trial, the most
common adverse events were hot flushes (37%), breast pain
(23.9%), nausea (16.3%), back pain (15.2%), and dyspnoea (13%),
with weight gain next at 11%. In both trials the dose of arzoxifene
had no influence on side effects. There was one deep vein
thrombosis in the American study, and two in the European study.
In the European study, 52 postmenopausal patients had
endometrial assessment (TVU at baseline and at least one
follow-up ultrasound at 12 weeks and every 6 months while on
arzoxifene), with the majority (83%) showing no change. Only 19%
required further investigation. There were no endometrial cancers,
and two cases of ovarian cysts (one in each dose arm). In the
American study, uterine evaluation involved baseline TVU, and
follow-up ultrasound at least every 6 months in the first year and
at least yearly thereafter. Sixty postmenopausal patients had
baseline evaluation and 46 had at least one follow-up TVU. One
patient (in the 20 mg/day arm) had vaginal bleeding attributed
to atrophic vaginitis, and five women (all in the 50 mg/day arm)
showed increased endometrial thickness. Of these five, only
one had further gynecological evaluation, with insufficient
tissue obtained for diagnosis. Again, no endometrial cancers
were diagnosed.
Overall both trials reached similar conclusions: arzoxifene
20 mg/day showed a numerical advantage over 50 mg/day in
efficacy in breast cancer, both doses exhibited satisfactory
tolerability, there was no significant estrogenic effect on
endometrium, and there was evidence of an antiresorptive effect
on bone in postmenopausal women.
Arzoxifene as a chemopreventive agent was also studied in a
phase II trial that randomized 199 women considered at high risk
of breast cancer to arzoxifene 20 mg/day versus placebo (Fabian
et al. 2006; Kimler et al. 2006). Fifty-two percent of patients were
premenopausal, whilst 47% of the postmenopausal women were
on hormone replacement therapy (HRT). At 6 months, arzoxifene
improved two risk biomarkers:
1. Mammographic breast density was significantly reduced
(P<0.001), both in terms of the total dense area (+3.8 cm2
versus –12.9 cm2) and the percent of breast with increased
density (+0.8% versus –4.6%) (Kimler et al. 2006)
2. IGF-1:IGFBP-3 ratio was significantly reduced (P=0.001)
(Fabian et al. 2006).
However, there was no change in a breast epithelial cell
cytomorphology risk index score (Masood index), assessed by
random periareolar fine-needle aspirate (Fabian et al. 2006). There
was a significant reduction (P=0.002) in osteocalcin level and no
increase in endometrial thickness.
Endometrial cancer
With the preclinical data suggesting arzoxifene did not induce
endometrial proliferation (Palkowitz et al. 1997; Sato et al. 1998;
Suh et al. 2001; Ma et al. 2002) and in some circumstances would
inhibit endometrial cancer cell lines in vitro (Dardes et al. 2001), a
Arzoxifene | proof of concept review
Core Evidence 2008;2(4)
Dose 20 mg/day 50 mg/day
American European American European
ORR (%) 19.2 40.5 7.4 36.4
CBR (%) 28.8 64.3 20.4 61.4
CBR, clinical benefit rate (ORR + stable disease for ≥6 months); ORR, objective response
rate (complete response + partial response).
Table 2 | Overall efficacy of arzoxifene in metastatic breast
cancer in phase II trials [Baselga et al. 2003
(European trial); Buzdar et al. 2003 (American trial)]
Tamoxifen sensitive Tamoxifen refractory
Dose 20 mg/day 50 mg/day 20 mg/day 50 mg/day
ORR (%) 30.4 8.0 10.3 6.9
CBR (%) 47.8 32.0 13.8 10.3
CBR, clinical benefit rate (ORR + stable disease for ≥6 months); ORR, objective response
rate (complete response + partial response).
Table 3 | Arzoxifene efficacy stratified by tamoxifen sensitivity
(Buzdar et al. 2003)phase II open-label trial was conducted using arzoxifene
20 mg/day in recurrent or advanced estrogen receptor- and/or
progesterone receptor-positive endometrial cancer (McMeekin et
al. 2003). Thirty-four patients were treated, 29 were assessable,
and adjuvant chemotherapy was allowed, although not salvage
chemotherapy or prior antiestrogen therapy; prior progestogen
therapy was permitted. The ORR was 31% (1 CR + 8 PR), CBR was
37.9% (9 responses + 2 stable disease for ≥6 months), and median
duration of response was 13.9 months. This was comparable or
better than historical controls treated with progestogens with
or without tamoxifen. Although encouraging, further use
of arzoxifene in this area has not yet been pursued by the
manufacturer (M￼nster 2006).
Phase III trial
The phase II trials in patients with breast cancer had shown
arzoxifene to produce results comparable to tamoxifen when it
was used in historic phase III trials against other endocrine agents
(M￼nster 2006). These studies had also identified 20 mg/day as
the preferred dose to take forward in the development of
arzoxifene. The data were thought to be compelling enough to
warrant a phase III trial of arzoxifene 20 mg/day versus tamoxifen
20 mg/day in locally advanced/metastatic breast cancer
(Deshmane et al. 2007).
The initial trial design aimed to recruit 480 women, aged
>50 years, with estrogen receptor- or progesterone receptor-
positive (or unknown), locally advanced/metastatic breast cancer.
Any previous chemotherapy had to be completed ≥6 months prior
to randomization, and patients were either hormone na￯ve or had
endocrine therapy ≥12 months prior to diagnosis of locally
advanced/metastatic disease. A planned interim efficacy analysis
was performed for the first 200 patients. This suggested
arzoxifene had an inferior response compared with tamoxifen
(Deshmane et al. 2007) and the data monitoring board
recommended trial cessation, which the sponsor accepted. By this
time a total of 368 patients had been recruited from 71 centers in
18 countries, with 353 available for final efficacy analysis.
The final efficacy analysis confirmed the interim analysis (Table 4)
(Deshmane et al. 2007). Tamoxifen showed a statistically
significant advantage over arzoxifene with regards to
progression-free survival, time to treatment failure, and on-study
progression-free survival. However, there was no significant
difference in ORR, CBR, median response duration, or overall
survival (Table 4).
Both arzoxifene and tamoxifen significantly reduced total
cholesterol, LDL, and high density lipoprotein (HDL) levels from
baseline. Both also significantly reduced osteocalcin levels in
postmenopausal women.
The most common adverse events were hot flushes, nausea,
sweating, and headache, although arzoxifene adverse events
were comparable with those from previous phase I and II trials.
There was one case of venous thromboembolism on arzoxifene
and two on tamoxifen.
The trial investigators could not offer a definitive explanation for
the poorer than expected performance of arzoxifene. There was
some speculation made about a higher arzoxifene dose perhaps
inducing a better response (in spite of the phase II trial results),
or that the longer half-life of tamoxifen or its active metabolite
(4-hydroxy-tamoxifen) may have produced a greater than
expected antitumor effect (Deshmane et al. 2007). However, on
the basis of these data arzoxifene was relegated to investigation
for treatment of postmenopausal osteoporosis, with the
manufacturer (Ely Lilly & Co.) no longer choosing to pursue the
drug as a breast cancer treatment.
Clinical potential
Throughout its development, arzoxifene had shown promise of
resurrecting the hopes for benzothiophene SERMs or of
possibly outperforming its benzothiophene relative, raloxifene,
by becoming what was thought to be the ideal SERM. In both
phase I and II studies arzoxifene showed similar endocrine
effects of decreasing FSH and LH levels with increasing SHBG
levels as had been reported with tamoxifen (L￸nning et al.
1995; Kostoglou-Athanassiou et al. 1997). However, with the
clinical results of the phase III trial (Deshmane et al. 2007)
arzoxifene suffered the same fate as raloxifene, being relegated
to investigation as an osteoporosis treatment and breast
cancer prophylaxis and no longer considered as a breast
cancer treatment. Thus, arzoxifene joins a number of other
SERMs such as droloxifene, which was also shown to be
inferior to tamoxifen in a phase III trial (Buzdar et al. 2002), or
idoxifene (Johnston et al. 2001) and toremifene (Pyrhonen et al.
1999), which were both shown to have similar efficacy and
side effect profiles and therefore provided no advantage
over tamoxifen.
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Arzoxifene Tamoxifen P value
Progression-free survival
(median; months)
4.0 7.5 0.007
Time to treatment failure
(median; months)
4.0 6.0 0.029
On-study progression free
survival (median; months)
4.0 7.5 0.009
Median response duration
(months)
11.9 11.9 0.41
Overall median survival (months) NAa 17.1 0.107
ORR (%) 23.6 27.2 0.46
CBR (%) 33.3 42.8 0.07
aNot available due to large proportion (85%) of censored values.
CBR, clinical benefit rate (ORR + stable disease for ≥6 months); ORR, objective response
rate (complete response + partial response).
Table 4 | Results achieved with arzoxifene compared with
tamoxifen in phase III trial in patients with estrogen
receptor- or progesterone receptor-positive
(or unknown) locally advanced/metastatic breast
cancer (Deshmane et al. 2007)257
Currently, the investigators of the phase III trial have not
provided a definite explanation for the less than expected
performance of arzoxifene. Some speculation has been made
about a higher arzoxifene dose or the potential confounding
effect of tamoxifen’s longer half-life or its active metabolite
effects (Deshmane et al. 2007). Meanwhile, other expert
commentators (M￼nster 2006) have only been able to speculate
on possible causes. Perhaps there is only a subpopulation of
arzoxifene responders, or perhaps indeed the dose used (20
mg/day) was in fact too low despite the phase II data. If the
latter is true, then the maximum tolerated dose needs to be
found and used (M￼nster 2006), which could even involve
multidose schedules versus once-daily regimes. However,
without the support of the manufacturer it would seem unlikely
the drug will be resurrected for clinical development in the
treatment of established breast cancer.
There are currently two ongoing or recently completed phase III
arzoxifene trials: an osteoporosis prevention trial
(NCT00085956, completed February 2007), and a study on
vertebral fracture and invasive breast cancer prevention in
postmenopausal women (NCT00088010, which has now
ceased recruiting).
In summary, arzoxifene is a triphenylethylene SERM with a fixed
ring structure similar to raloxifene. Initial preclinical and clinical
phase I/II data suggested that it might be the ideal SERM with
properties that would allow it to replace tamoxifen as the SERM
and antiestrogen of choice in the treatment of established
hormone receptor positive breast cancer. However, the results
of a phase III randomized trial showed arzoxifene to be inferior
to tamoxifen in terms of time to progression, which was the
primary endpoint. As a result the trial was terminated and the
development of arzoxifene for established breast cancer was
discontinued. There are currently two remaining ongoing trials
that have finished recruitment studying the effect of arzoxifene
in the prevention of osteoporosis and breast cancer,
respectively. The results of these trials are awaited with interest.
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